Autoimmungastritis

Die Autoimmungastritis (AIG) ist eine chronische immunvermittelte Entzündung der Magenkorpus/-fundusschleimhaut, die zur progressiven Atrophie der oxyntischen Magendrüsen (AOM) und deren konsekutiven Funktionsverlust führt. Mögliche klinische Folgen der AIG sind Eisenmangelanämie, perniziöse Anämie, neuroendokrine Tumoren des Magens (gNET) und das Magenkarzinom. Dieser Beitrag bietet eine Übersicht interdisziplinärer Aspekte zur Diagnostik und Therapie der AIG.

Abstract

Autoimmune gastritis (AIG) is a chronic immune-mediated inflammation of the gastric corpus/fundus mucosa leading to progressive atrophy of the oxyntic gastric glands (AOM) and their consecutive loss of function. Possible clinical consequences of AIG include iron deficiency anemia, pernicious anemia, gastric neuroendocrine tumors (gNET), and gastric adenocarcinoma. This article provides a review of interdisciplinary aspects of the diagnosis and treatment of AIG.

Schlüsselwörter

Autoimmungastritis - Eisenmangelanämie - perniziöse Anämie - neuroendokrine Tumoren des Magens (gNET) - Magenkarzinom

Key words

autoimmune gastritis - iron deficiency anemia - pernicious anemia - gastric neuroendocrine tumors - gastric cancer

Publication History

Article published online:
11 April 2022

• Literatur

• 1 Rustgi SD, Bijlani P, Shah SC. Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therap Adv Gastroenterol 2021; 14
• 2 Lahner E, Esposito G, Galli G. et al. Atrophic gastritis and pre-malignant gastric lesions. Transl Gastrointest Cancer 2015; 4: 272-281
• 3 Toh BH, Chan J, Kyaw T. et al. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol 2012; 42: 269-278
• 4 Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc 2013; 77: 284-292
• 5 Alexander SM, Retnakumar RJ, Chouhan D. et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol 2021; 12: 713955
• 6 Venerito M, Radünz M, Reschke K. et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther 2015; 41: 686-693
• 7 Laisk T, Lepamets M, Koel M. et al. Genome-wide association study identifies five risk loci for pernicious anemia. Nat Commun 2021; 12: 3761
• 8 Newbold HL. Vitamin B-12, megaloblastic madness, and the founding of Duke University. Med Hypotheses 1988; 27: 231-240
• 9 Carabotti M, Lahner E, Esposito G. et al. Upper gastrointestinal symptoms in autoimmune gastritis. Medicine (Baltimore) 2017; 96: e5784
• 10 Lahner E, Zagari RM, Zullo A. et al. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian So. Dig Liver Dis 2019; 51: 1621-1632
• 11 Terao S, Suzuki S, Yaita H. et al. Multicenter study of autoimmune gastritis in Japan: Clinical and endoscopic characteristics. Dig Endosc 2020; 32: 364-372
• 12 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
• 13 Shah SC, Piazuelo MB, Kuipers EJ. et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology 2021; 161: 1325-1332.e7
• 14 Dixon MF, Genta RM, Yardley JH. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181
• 15 Coati I, Fassan M, Farinati F. et al. Autoimmune gastritis: Pathologist’s viewpoint. World J Gastroenterol 2015; 21: 12179
• 16 Weise F, Vieth M, Reinhold D. et al. Gastric cancer in autoimmune gastritis: A case‐control study from the German centers of the staR project on gastric cancer research. United Eur Gastroenterol J 2020; 8: 175-184
• 17 Venerito M, Vasapolli R, Malfertheiner P. Prevention, early diagnosis and therapy of gastric cancer. MMW Fortschr Med 2016; 158: 39-43
• 18 Rusak E, Chobot A, Krzywicka A. et al. Anti-parietal cell antibodies – diagnostic significance. Adv Med Sci 2016; 61: 175-179
• 19 Venerito M, Varbanova M, Röhl FW. et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J Clin Pathol 2016; 69: 677-685
• 20 Malfertheiner P, Megraud F, O’Morain CA. et al. Management of helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2016; 66: 6-30
• 21 Gupta S, Li D, El Serag HB. et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158: 693-702
• 22 Sugano K, Tack J, Kuipers EJ. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-1367
• 23 Song M, Latorre G, Ivanovic-Zuvic D. et al. Autoimmune diseases and gastric cancer risk: A systematic review and meta-analysis. Cancer Res Treat 2019; 51: 841-850
• 24 Murphy G, Dawsey SM, Engels EA. et al. Cancer Risk After Pernicious Anemia in the US Elderly Population. Clin Gastroenterol Hepatol 2015; 13: 2282-2289.e4
• 25 Wall AJ, Whittingham S, Mackay IR. et al. Prednisolone and gastric atrophy. Clin Exp Immunol 1968; 3: 359-366
• 26 Moayyedi PM, Lacy BE, Andrews CN. et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112: 988-1013
• 27 AWMF. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. AWMF-Register-Nr. 032/009OL. 2019 https://www.awmf.org/leitlinien/detail/ll/032-009OL.html . Stand: 04.02.2022
• 28 Rinke A, Wiedenmann B, Auernhammer C. et al S2k-Leitlinie Neuroendokrine Tumore. AWMF-Register-Nr. 021-27. 2018 https://www.awmf.org/uploads/tx_szleitlinien/021-026l_S2k_Neuroendokrine_Tumore_2018-07.pdf . Stand: 04.02.2022